The Importance of Treatment at a Specialty Center for Sarcomas

Print this article Add to Favorites
 

An ESUN Article

Elizabeth Goldstein-Rice

There are numerous and important reasons why someone who has been diagnosed with sarcoma should be treated at a center where there is an interdisciplinary medical team that has experience in treating this rare disease.

Let's say you've received a new diagnosis of sarcoma. You have an initial diagnosis, as well as an expert second opinion to fine-tune that diagnosis, and are now faced with the decision of where to have your treatment. Understandably, most patients like you would prefer to be treated someplace close to home, perhaps at a local oncology clinic recommended by close friends, co-workers or relatives, who had good experiences using locally available medical services. However, when it comes to the treatment of sarcomas, the advice of the experts is to take the leap and find your way to a major medical center with a specialty in treating rare, life-threatening sarcomas.

Success Rates at Sarcoma Centers

Video: Sarcoma CentersIn a meticulous review of 4,205 sarcoma case records covering a 20-year period, researchers at the University of Miami School of Medicine found significantly higher success rates for patients treated at major sarcoma centers. The study entitled, "Should Soft Tissue Sarcomas Be Treated at High-volume Centers? An Analysis of 4205 Patients," compares patient demographics; tumor type, size and location; and therapy given at low volume (LVC) and high-volume (HVC) medical facilities. [1] Patients seen at HVC were in more critical condition than those treated at the LVC, having higher-grade tumors and correspondingly worse prognoses. Yet, patients treated at the HVC had better outcomes than their less critical counterparts treated at LVC. Patients treated at HVC were offered a broader range of treatment options, including radiation and chemotherapy in addition to surgery. The study states "a greater proportion of patients treated at HVC received radiation therapy (43% vs 24.2%, P < 0.001) and chemotherapy (14.7% vs. 6.3%, P < 0.001)." [1] The addition of radiation and chemotherapy is credited with the better outcomes for these patients.

Not only did patients at HVC benefit from the use of a combination of therapies, those who had sarcomas in their extremities were also less likely to have amputations. LVC amputated 13.8% of the time, in contrast to 9.4% at HVC, where doctors have more experience with limb preservation strategies. [1] While this might not, at first glance, seem like a large margin, for those who are able to complete their cancer treatments without the loss of life or limb, this is huge!

What would explain this disparity? According to the authors, "STSs are rare. This paucity leaves most healthcare institutions with low case volumes and outdated or inadequate resources, which impede the ability to offer optimal treatment of these rare and often complicated tumors." [1]

Whoops Surgeries

A study in the UK finds that "The most significant factors affecting survival were grade (high versus low) and depth of the tumour" and the expertise of the treatment center. [2] In this study, the argument is made that patients have better outcomes at large hospital centers largely because local control is much better. [2] In performing surgery to remove a sarcoma, it is extremely important to remove the entire tumor and surrounding tissue to achieve a wide margin between cancerous cells and healthy tissue. There's even a name for one of the common errors, in which the surgeon performs a “whoops” procedure. [2]. According to the authors, "This is when a lump is excised, usually with little forethought and without a biopsy and the surgeon is then surprised when the pathologist reports it as a sarcoma (hence the term 'whoops') .... most authors now agree that wide re-excision to obtain clear margins is necessary as residual tumour will be found in anything between 30 and 60% of cases." [2] Needless to say, one surgery is preferable to two surgeries especially where the second one is totally avoidable. Local recurrence (LR) rates are much lower when the surgery is done correctly.

Local Recurrence and Sarcoma Centers

Video: Dr. Randall discusses sarcoma centersAs the UK study states, "Patients with an adequate excision had a LR rate of 26% compared to a 40% risk in patients with an inadequate excision." [2] This study concludes, as did the previous study above, that patients should be referred exclusively to specialized medical centers that see a high volume of rare cancers "for optimal treatment, survival and functional outcome." [1, 2]

Fritz Eilber and Frederick Eilber of the University of California Los Angeles School of Medicine further underscore the importance of avoiding recurrence due to the use of incorrect surgical procedures. In their article "Surgical Management of Soft Tissue Tumors: Avoiding the Pitfalls," they conclude, "The optimal treatment of locally recurrent disease is to prevent it, which necessitates aggressive surgical treatment of the primary disease, because adjuvant therapies cannot compensate for inadequate surgery." [3] The best way to avoid surgical errors for rare tumors (and all sarcomas are rare) is to be treated at a specialty center with an experienced multidisciplinary team [1, 2, 3].

Some Additional Considerations

In addition to the benefits of experienced medical teams, reduced surgical risk and documented lower local recurrence rates, other factors to consider in selecting a treatment center include:

Patients evaluating treatment centers should also know that even the best sarcoma centers may not inform patients of, or offer to refer patients to, outside facilities for specialized services that are only available in a limited number of locations. For example, according to The National Association for Proton Therapy, proton beam therapy, an effective treatment for some sarcomas, is only available at 5 sites within the United States. A hospital that has its own IMRT (Intensity-Modulated Radiation Therapy) technology is likely to encourage patients to use IMRT rather than go elsewhere in order to receive proton beam therapy. Patients wanting to know about a wide range of treatment options should make sure they get second opinions from more than one institution and do some research ahead of time regarding the therapies offered at each one.

Given this body of evidence that treatment at an HVC is superior to that at local facilities, British researchers did a study to find out why patients didn't find their way to sarcoma centers more quickly [4]. The authors of "Delays in Referral of Soft Tissue Sarcomas" begin with the premise that "It is well established that soft tissue sarcomas are more effectively treated in a specialist centre" [4]. They go on to produce an involved analysis of patient demographics, key dates in patient contact with medical professionals and the type of initial treatments provided. The patients were rarely found to be the cause of extended delays, as the authors note "although some patients are more willing to tolerate symptoms, in general, patients present quickly to a medical professional and therefore do not contribute significantly to delay in reaching a specialist centre for treatment." [4] In other words, people with life-threatening sarcomas are not ignoring sound medical advice; they often aren't receiving it in the first place! The researchers ultimately establish that medical professionals are responsible for most delays, primarily because they lack knowledge of published cancer treatment guidelines [4].

Summary

Patients need help finding the right place of treatment. Online sarcoma self-help and support groups are two methods that patients are using to find their way to sarcoma centers. Patients depend on the medical professionals around them to tell them the truth about their condition and what they have to do to combat it, even when it means leaving a familiar local practice for the big city hospital centers. They also need help understanding that sarcoma-related clinical trials are not all wild experiments, but may be the fastest route to remission. And if you are that sarcoma patient, you do deserve nothing but the best!

Cancer Centers with a Sarcoma Focus
California

Cedars-Sinai Cancer Program
Cedars-Sinai, located in Los Angeles, is a patient-centered, comprehensive and specialized cancer program. On their website, they state, "At the Cedars-Sinai Cancer Program, dozens of nationally recognized programs and services are all under one interconnected, medical "roof"--an important benefit to cancer sufferers. Patients can be confident that every resource of this remarkable organization is brought to bear in delivering leading-edge healthcare services."

UCLA Sarcoma Program
The UCLA Sarcoma Program provides innovative multidisciplinary treatment for adults and children with sarcoma at any stage of the disease. UCLA is one of the three busiest sarcoma centers in the nation. On an annual basis they evaluate over 800 patients with sarcoma, 500 of which undergo surgery at UCLA. At our weekly sarcoma conference physicians specializing in sarcoma from surgical oncology, orthopedic oncology, medical oncology, radiation oncology, pediatric oncology, pathology and radiology formulate and coordinated optimal treatment strategies for individual patients

Florida
H. Lee Moffitt Cancer Center and Research Institute
The H. Lee Moffitt Cancer Center and Research Institute located at the University of South Florida in North Tampa, Florida brings together experts from a variety of cancer specialties to determine the best treatment plan for each patient, while linking together the Center’s extensive array of support services. As part of a group of National Cancer Institute Comprehensive Cancer Centers, Moffitt focuses on the development of early stage translational research aimed at the rapid translation of scientific discoveries to benefit patient care. The Sarcoma Program at the center takes an interdisciplinary approach to treating sarcomas.

Kansas

Sarcoma Institute at Menorah Medical Center
The Sarcoma Institute at Menorah Medical Center is a multi-disciplinary team of physicians, nurses, and allied health professionals dedicated to the care and treatment of patients with bone and soft tissues tumors. From infants to seniors, the professionals of the Sarcoma Institute treat patients with both primary malignant and benign tumors of the bone and soft tissues, as well as metastatic cancer of the bone. The Institute provides state-of-the-art treatments including surgical, medical and radiation, in a combined modality to offer patients the most effective care. Both research and education play a crucial role in the Institute by enhancing patient knowledge and continuing to enhance the field of sarcoma. The Institute is located in Overland Park, Kansas.

Maryland

The Johns Hopkins Sarcoma Center, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins
Located in Baltimore, Maryland, The Sarcoma Center at Johns Hopkins provides comprehensive care for pediatric and young adult patients with bone and soft tissue sarcomas. The Center uses a multidisciplinary team approach to care and treatment, which includes pediatric and adult medical oncology, surgery, pathology, diagnostic radiology, orthopaedics, radiotherapy and plastic surgery. Cases are reviewed by a multidisciplinary team at weekly conferences.

Massachusetts

Dana-Farber Cancer Institute
Located in Boston, Massachusetts, the Dana Farber Cancer Institute is a teaching affiliate of the Harvard Medical School. On their website, they state, "The Center for Sarcoma and Bone Oncology has dedicated specialty expertise in the pathologic and radiologic assessment of sarcoma, the application of novel soft-tissue and bone reconstructive techniques permitting limb salvage, and access to the most promising new therapies for these malignancies."

Massachusetts General Hospital
Center for Sarcoma & Connective Tissue Oncology

Michigan

University of Michigan Comprehensive Cancer Center
Located in Ann Arbor, Michigan, the UM Comprehensive Cancer Center is associated the UM's Medical School. On their website, they state, "The Center was established in 1986, and soon after was designated a "comprehensive" center by the National Cancer Institute.  he U-M Cancer Center has more than 200 cancer clinicians and researchers. These specialists work together in multidisciplinary teams to rapidly bring new prevention, detection and treatment discoveries to more than 25 cancer care clinics."

New York

Columbia Weill Cornell Cancer Center at the Herbert Irving Comprehensive Cancer Center
Located in New York City, the Columbia Weill Cornell Cancer Center is part of the Herbert Irving Comprehensive Cancer Center in the New York-Presbyterian complex, which forms the university hospitals for Columbia University and Cornell University.  On their website, they state, "Columbia Weill Cornell Cancer Centers provide comprehensive care for children and adults with primary and metastatic bone and soft tissue tumors."

Memorial Sloan-Kettering Cancer Center (MSK or MSKCC)
Located in New York City, Memorial Sloan-Kettering Cancer Center (MSKCC) has been dealing in cancer treatment and care for over 100-years. On their website, they state, "Memorial Sloan-Kettering doctors generate more than half of the world's research publications on soft-tissue sarcomas and have probably the largest experience with these tumors of any medical group."

Roswell Park Cancer Institute (RPCI)
The Roswell Park Cancer Institute (RPCI) locate in Buffalo, New York, is a National Cancer Institute designated comprehensive cancer center.  RPCI patients benefit from a customized, comprehensive care program developed by a multidisciplinary team of cancer specialists. The program addresses the medical, nutritional, emotional, and spiritual needs of each patient from diagnosis through treatment and rehabilitation, discharge and follow-up care.  Roswell Park Cancer Institute’s (RPCI) experts in soft-tissue sarcoma include specialists in surgery, medical oncology, radiation oncology, diagnostic radiology, pathology and rehabilitation support. Treatment approaches for this disease include conservative operations, combined with radiation therapy and/or chemotherapy, which offer patients a high rate of tumor control while avoiding amputation.

Oregon

Oregon Health & Science University Sarcoma Program

Pennsylvania

Fox Chase Cancer Center (FCCC)
Located in Philadelphia, Pennsylvania, Fox Chase Cancer Center (FCCC) is an independent, nonprofit institution devoted to improving cancer treatment and prevention. In 1904, the Fox Chase Cancer Center Hospital, which was then called the American Oncologic Hospital, became the country's first cancer hospital. The Center was formed in 1974 to unite the Hospital with the Institute for Cancer Research, founded in 1927.

Texas

M. D. Anderson Cancer Center
Located in Houston, Texas, M. D. Anderson has built a "worldwide reputation for excellence in cancer patient care, research, education and prevention".  On their website, they state, "Patients at M. D. Anderson's Sarcoma Center have a five-year survival rate well above the national average, and an outstanding 80% rate for classical osteosarcoma.  Our center diagnoses, treats and manages sarcomas of the soft tissue and bone, using the latest technology available."

Utah

Huntsman Cancer Institute (University of Utah)
Located in Salt Lake City, Utah, The Huntsman Cancer institute operates a hospital-based patient care center in association with the Health Sciences Center at the University of Utah. On their website, they state, "The Huntsman Cancer Institute Sarcoma Service, in addition to engaging in comprehensive clinical care, has ongoing, state of the art, basic science studies investigating the causes of sarcomas." 

Washington

Seattle Cancer Care Alliance – Sarcoma Service
The Seattle Cancer Care Alliance (SCCA) is a partnership between three leading cancer centers: the Fred Hutchinson Cancer Research Center, UW Medicine, and Children's Hospital and Regional Medical Center. The Alliance’s Sarcoma Service, which began in 1986, offers sarcoma patients the best of the Pacific Northwest's world-class cancer research and patient-care practices. It sees about 500 adults and 200 children a year who are newly diagnosed with sarcomas of various types. The majority of its patients come from outside the Western Washington region. It offers a multidisciplinary approach to sarcoma treatment, including access to new treatments and procedures through clinical trials, innovative programs such as the Sarcoma PET Imaging Program, Sarcobase one of the first sarcoma patient registries in North America and the first at a cancer center, as well as overlapping pediatric and adult programs, to provide continuity of care to young patients who can continue to see the same doctors as they grow to adulthood.

Washington, DC

Washington Cancer Institute and Lombardi Cancer Center
Located in Washington, DC, The Washington Cancer Institute and Lombardi Cancer Center is affiliated with Georgetown University. On their website, they state, "We have extensive experience treating both bone and soft tissue tumors of the extremities, pelvis and shoulder girdle. We have performed more than 3,000 tumor operations since 1979. We are leaders in limb-sparing surgery and have pioneered many surgical techniques in use at this and other cancer centers."

References

[1] "Should Soft Tissue Sarcomas Be Treated at High-volume Centers? An Analysis of 4205 Patients", by Juan C. Gutierrez, MD, Eduardo A. Perez, MD, Frederick L. Moffat, MD, Alan S. Livingstone, MD, Dido Franceschi, MD, and Leonidas G. Koniaris, MD, Annals of Surgery, Volume 245, Number 6, June 2007.

[2] "Should Soft Tissue Sarcomas be Treated at a Specialist Centre?", by A. A. Bhangu, J. A. S. Beard, and R. J. Grimer, Sarcoma, V. 8 (2004), Issue 1, Pages 1-6.

[3] "Surgical Management of Soft Tissue Tumors: Avoiding the Pitfalls", By Fritz C. Eilber, MD, and Frederick R. Eilber, MD, American Society of Clinical Oncology Educational Book. ASCO 2005.

[4] "Delays in Referral of Soft Tissue Sarcomas", by G. D. Johnson, G. Smith, A. Dramis, and R. J. Grimer, Sarcoma, V. 2008, Article ID 378574, 7 pages.

V5N6 ESUN Copyright © 2008 Liddy Shriver Sarcoma Initiative.